BAX Stock - Baxter International Inc.
Unlock GoAI Insights for BAX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $10.64B | $10.36B | $10.06B | $12.15B | $11.67B |
| Gross Profit | $3.98B | $4.15B | $3.55B | $4.72B | $4.59B |
| Gross Margin | 37.5% | 40.1% | 35.3% | 38.9% | 39.3% |
| Operating Income | $14.00M | $707.00M | $-2,845,000,000 | $1.35B | $1.62B |
| Net Income | $-649,000,000 | $2.66B | $-2,433,000,000 | $1.28B | $1.10B |
| Net Margin | -6.1% | 25.6% | -24.2% | 10.6% | 9.4% |
| EPS | $-1.27 | $5.25 | $-4.83 | $2.56 | $2.17 |
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 31st 2025 | Argus | Downgrade | Hold | - |
| August 4th 2025 | Stifel | Downgrade | Hold | $25 |
| August 1st 2025 | Goldman | Downgrade | Neutral | $25 |
| February 26th 2025 | Goldman | Resumed | Buy | $42 |
| February 24th 2025 | Argus | Upgrade | Buy | - |
| February 20th 2025 | Barclays | Resumed | Overweight | $39 |
| July 15th 2024 | Morgan Stanley | Downgrade | Underweight | $30← $39 |
| May 30th 2024 | Goldman | Initiation | Neutral | $36 |
| May 10th 2024 | TD Cowen | Downgrade | Hold | $40 |
| May 30th 2023 | Morgan Stanley | Resumed | Equal Weight | $45 |
| March 29th 2023 | UBS | Initiation | Neutral | $43 |
| January 6th 2023 | Morgan Stanley | Downgrade | Equal Weight | $55 |
| January 5th 2023 | Raymond James | Downgrade | Market Perform | - |
| January 3rd 2023 | BofA Securities | Downgrade | Neutral | $55← $66 |
| December 19th 2022 | JP Morgan | Downgrade | Neutral | $55← $68 |
Earnings History & Surprises
BAXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 19, 2026 | $0.53 | — | — | — |
Q4 2025 | Oct 30, 2025 | $0.60 | $0.69 | +15.0% | ✓ BEAT |
Q3 2025 | Jul 31, 2025 | $0.60 | $0.59 | -1.7% | ✗ MISS |
Q2 2025 | May 1, 2025 | $0.48 | $0.55 | +13.8% | ✓ BEAT |
Q1 2025 | Feb 20, 2025 | $0.53 | $0.58 | +9.8% | ✓ BEAT |
Q4 2024 | Nov 8, 2024 | $0.78 | $0.80 | +2.6% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $0.66 | $0.68 | +2.7% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $0.61 | $0.65 | +7.1% | ✓ BEAT |
Q1 2024 | Feb 8, 2024 | $0.86 | $0.88 | +2.3% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $0.66 | $0.68 | +3.0% | ✓ BEAT |
Q3 2023 | Jul 27, 2023 | $0.59 | $0.55 | -6.8% | ✗ MISS |
Q2 2023 | Apr 27, 2023 | $0.48 | $0.59 | +22.9% | ✓ BEAT |
Q1 2023 | Feb 9, 2023 | $0.94 | $0.88 | -6.4% | ✗ MISS |
Q4 2022 | Oct 27, 2022 | $0.82 | $0.82 | 0.0% | = MET |
Q3 2022 | Jul 28, 2022 | $0.88 | $0.87 | -1.1% | ✗ MISS |
Q2 2022 | Apr 28, 2022 | $0.80 | $0.93 | +16.3% | ✓ BEAT |
Q1 2022 | Feb 17, 2022 | $1.03 | $1.04 | +1.0% | ✓ BEAT |
Q4 2021 | Oct 28, 2021 | $0.94 | $1.02 | +8.5% | ✓ BEAT |
Q3 2021 | Jul 29, 2021 | $0.74 | $0.80 | +8.1% | ✓ BEAT |
Latest News
Baxter Highlights Presentation At American Society of Health System Pharmacists Meeting Showing Smart Infusion Pump Electronic Medical Record Integration May Improve Patient Safety And Nursing Bedside Productivity
📈 PositiveMorgan Stanley Maintains Underweight on Baxter Intl, Lowers Price Target to $15
📉 NegativeBaxter Permanently Removes Life2000 Ventilation System; FDA Has Identified This Recall As The Most Serious Type, This Device May Cause Serious Injury Or Death If You Continue To Use It
📉 NegativeCitigroup Maintains Neutral on Baxter Intl, Lowers Price Target to $21
➖ NeutralGoldman Sachs Maintains Neutral on Baxter Intl, Lowers Price Target to $22
➖ NeutralUBS Maintains Neutral on Baxter Intl, Lowers Price Target to $21
➖ NeutralArgus Research Downgrades Baxter Intl to Hold
📉 NegativeBaxter tanks after lower FY expectations, Q3 revenue miss
📉 NegativeBaxter Intl Sees Q4 Adj EPS $0.52-$0.57 vs $0.70 Est; Sees Sales $2.808B vs $3.005B Est
📉 NegativeBaxter Intl Lowers FY2025 Adj EPS Guidance from $2.42-$2.52 to $2.35-$2.40 vs $2.44 Est; Lowers FY2025 Sales Guidance from $11.274B-$11.380B to $11.061B-$11.167B vs $11.312B Est
📉 NegativeBaxter International shares are trading lower after the company reported mixed Q3 results.
📉 NegativeBaxter Intl Sees Q4 Adj EPS $0.52-$0.57 vs $0.70 Est
📉 NegativeBaxter Intl Q3 Adj. EPS $0.69 Beats $0.60 Estimate, Sales $2.835B Miss $2.875B Estimate
➖ NeutralEvercore ISI Group Maintains Outperform on Baxter Intl, Lowers Price Target to $31
➖ NeutralShares of medical technology stocks are trading lower after the US opened national security investigations into imports of medical equipment, industrial machinery and robotics.
📉 NegativeBaxter International 13G Filing Shows PZENA INVESTMENT MANAGEMENT Reported A Stake Of 10.8% As Of August 31, 2025, Vs Prior Stake Of 7.7%
📈 PositiveBaxter slumps as Medical Products & Therapies drive Q2 revenue miss
📉 NegativeFrequently Asked Questions about BAX
What is BAX's current stock price?
What is the analyst price target for BAX?
What sector is Baxter International Inc. in?
What is BAX's market cap?
Does BAX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BAX for comparison